JPWO2020257536A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020257536A5 JPWO2020257536A5 JP2021575320A JP2021575320A JPWO2020257536A5 JP WO2020257536 A5 JPWO2020257536 A5 JP WO2020257536A5 JP 2021575320 A JP2021575320 A JP 2021575320A JP 2021575320 A JP2021575320 A JP 2021575320A JP WO2020257536 A5 JPWO2020257536 A5 JP WO2020257536A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- patient
- inhibitor
- cdk4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863153P | 2019-06-18 | 2019-06-18 | |
| US62/863,153 | 2019-06-18 | ||
| US201962907375P | 2019-09-27 | 2019-09-27 | |
| US62/907,375 | 2019-09-27 | ||
| PCT/US2020/038557 WO2020257536A1 (en) | 2019-06-18 | 2020-06-18 | Patient selection for enhancement of anti-tumor immunity in cancer patients |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022536854A JP2022536854A (ja) | 2022-08-19 |
| JPWO2020257536A5 true JPWO2020257536A5 (https=) | 2023-06-27 |
| JP2022536854A5 JP2022536854A5 (https=) | 2023-06-27 |
| JP7812232B2 JP7812232B2 (ja) | 2026-02-09 |
Family
ID=74040931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575320A Active JP7812232B2 (ja) | 2019-06-18 | 2020-06-18 | 癌患者における抗腫瘍免疫の増強のための患者選択 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220175787A1 (https=) |
| EP (1) | EP3986410A4 (https=) |
| JP (1) | JP7812232B2 (https=) |
| KR (1) | KR20220024540A (https=) |
| CN (1) | CN114222577A (https=) |
| AU (1) | AU2020296087A1 (https=) |
| CA (1) | CA3143339A1 (https=) |
| TW (1) | TW202114684A (https=) |
| WO (1) | WO2020257536A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| WO2022258002A1 (zh) * | 2021-06-10 | 2022-12-15 | 上海岸阔医药科技有限公司 | 治疗化疗相关的胃肠道副作用的化合物和方法 |
| CN118215481A (zh) * | 2021-07-01 | 2024-06-18 | 海南先声再明医药股份有限公司 | 晚期和/或转移性Trop-2过表达癌症患者的联合治疗 |
| WO2023064913A1 (en) * | 2021-10-14 | 2023-04-20 | Wisconsin Alumni Research Foundation | K17 as a biomarker for tumor response to immunotherapy |
| CN115019880B (zh) * | 2022-05-05 | 2024-01-09 | 中山大学附属第一医院 | 一种肝癌预后模型及其构建方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102051881B1 (ko) | 2010-10-25 | 2019-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| EP2976642A4 (en) | 2013-03-15 | 2016-09-21 | Harvard College | METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT |
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| AU2017359333B2 (en) * | 2016-11-08 | 2024-03-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| IL303038B2 (en) * | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| WO2018156812A1 (en) * | 2017-02-22 | 2018-08-30 | G1 Therapeutics, Inc. | Treatment of egfr-driven cancer with fewer side effects |
| WO2019108589A1 (en) * | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| US10122265B1 (en) | 2018-01-03 | 2018-11-06 | Intel Corporation | Reducing electromagnetic interference in switching regulators |
| TW202327610A (zh) * | 2021-08-30 | 2023-07-16 | 美商G1治療公司 | 具有檢查點抑制劑抗性或抗性易感性之晚期性/轉移性癌症之改良治療 |
-
2020
- 2020-06-18 EP EP20825571.1A patent/EP3986410A4/en active Pending
- 2020-06-18 CN CN202080056941.0A patent/CN114222577A/zh active Pending
- 2020-06-18 AU AU2020296087A patent/AU2020296087A1/en not_active Abandoned
- 2020-06-18 KR KR1020227001251A patent/KR20220024540A/ko not_active Ceased
- 2020-06-18 JP JP2021575320A patent/JP7812232B2/ja active Active
- 2020-06-18 WO PCT/US2020/038557 patent/WO2020257536A1/en not_active Ceased
- 2020-06-18 TW TW109120659A patent/TW202114684A/zh unknown
- 2020-06-18 CA CA3143339A patent/CA3143339A1/en active Pending
-
2021
- 2021-12-17 US US17/554,940 patent/US20220175787A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202034959A (zh) | 抗體-藥物結合物與parp抑制劑之組合 | |
| US12257245B2 (en) | Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors | |
| Lefler et al. | Immunotherapy resistance in solid tumors: mechanisms and potential solutions | |
| Ma et al. | Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation | |
| Barot et al. | Recent advancement in targeted therapy and role of emerging technologies to treat cancer | |
| EP3581586A1 (en) | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab | |
| US20220175787A1 (en) | Patient selection for enhancement of anti-tumor immunity in cancer patients | |
| US20210015787A1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| JP2024524461A (ja) | 進行性および／または転移性ｔｒｏｐ－２過剰発現ガンを有する治療困難患者における併用治療 | |
| US20240360247A1 (en) | Compositions and methods for treatment of cancer | |
| JPWO2020257536A5 (https=) | ||
| EA037271B1 (ru) | Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге | |
| CN111246881B (zh) | Pd-1抗体用于治疗肿瘤的用途 | |
| WO2022188850A1 (zh) | 包含己酸羟孕酮的抗肿瘤联合制剂及其用途 | |
| Hu et al. | Mechanism of LINC01018/miR-182-5p/Rab27B in the immune escape through PD-L1-mediated CD8+ T cell suppression in glioma | |
| JP2023517671A (ja) | ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置 | |
| CA3250299A1 (en) | CANCER TREATMENT | |
| CN106539812B (zh) | 环二核苷酸cGAMP在抗结直肠癌肝转移中的应用 | |
| WO2023073429A1 (en) | Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors | |
| Dai Phung et al. | Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers | |
| CN117500493A (zh) | 使用pd-1抗体组合治疗恶性瘤 | |
| WO2020160409A1 (en) | Methods of treating cancer using a combination of tumor membrane vesicles and metformin | |
| WO2026086908A1 (zh) | Ast-3424治疗免疫检查点抑制剂耐药的癌症患者 | |
| Gang et al. | Whether AI+ CDK4/6i+ HP is suitable treatment for three positive metastatic breast cancer patient with renal insufficiency caused by type 2 diabetes | |
| WO2025247378A1 (zh) | Ast-3424治疗肝癌 |